{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:20:29Z","timestamp":1780496429849,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T00:00:00Z","timestamp":1408665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson Services, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The proteasome inhibitor, bortezomib, potentially increases cell sensitivity to chemotherapy. This study was performed to determine the overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>), overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>), progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and toxicity of <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> (cyclophosphamide, doxorubicin, vincristine and prednisolone) compared to <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> + bortezomib chemotherapy in mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) patients at first relapse. Forty\u2010six patients were randomly assigned to standard dose <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u00a0\u00b1\u00a0bortezomib 1\u00b76\u00a0mg\/m<jats:sup>2<\/jats:sup> given on a 21\u2010d cycle for up to eight cycles of treatment. Median age was 71\u00a0years (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> arm) and 69\u00a0years (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib arm). Median Eastern Cooperative Oncology Group performance status was 1 (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) and 0 (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib) with 65% and 52%, respectively, having a disease stage of <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 47\u00b78% (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) and 82\u00b76% (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib). Complete response rate was 21\u00b77% (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) vs. 34\u00b78% (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib); partial response rate was 26\u00b71% (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) vs. 47\u00b78% (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib). Median <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 11\u00b78\u00a0months (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) and 35\u00b76\u00a0months (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib) (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b701, Hazard ratio [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>] 0\u00b737 [95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 0\u00b716\u20130\u00b783)] and there was a non\u2010significant improvement in <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>: 8\u00b71\u00a0months (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) and 16\u00b75\u00a0months (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib) [<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b712, <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0\u00b760 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0\u00b731\u20131\u00b715)]. Severe (\u2265grade 3) sensory neuropathy was similar in both arms (4\u00b73% <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> vs. 6\u00b75% <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010bortezomib). We conclude that the addition of bortezomib to <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> chemotherapy for relapsed <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> significantly improves outcome with a manageable increase in toxicity.<\/jats:p>","DOI":"10.1111\/bjh.13101","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T10:21:18Z","timestamp":1408702878000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma"],"prefix":"10.1111","volume":"168","author":[{"given":"Michelle","family":"Furtado","sequence":"first","affiliation":[{"name":"Derriford Hospital Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod","family":"Johnson","sequence":"additional","affiliation":[{"name":"St. James Institute of Oncology Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Kruger","sequence":"additional","affiliation":[{"name":"Royal Cornwall Hospital Truro UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Turner","sequence":"additional","affiliation":[{"name":"Torbay Hospital Torbay UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[{"name":"Derriford Hospital Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00120-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08340.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08820.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199679"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25509"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07775.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1498"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.5045\/kjh.2012.47.1.53"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.8051","article-title":"Schedule of bortezomib administration may be an important determinant of single agent activity in patients with relapsed or refractory follicular and mantle cell NHL","volume":"25","author":"O'Connor O.A.","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.440.440","article-title":"The addition of rituximab to fludarabine and cyclophosphamide (FC) chemotherapy improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the Randomised UK National Cancer Research Institute (NCRI) Trial","volume":"118","author":"Rule S.","year":"2011","journal-title":"Blood: ASH Annual Meeting Abstracts"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"e_1_2_8_28_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.","year":"2008"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404959"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404511"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13101","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:54:50Z","timestamp":1696326890000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/bjh.13101"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13101","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,22]]},"assertion":[{"value":"2014-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}